Company: BLNE
Filing Date: 2025-03-26
Form Type: 424B7
Source: 0001641172-25-000695
Chunk: 12

Company: Beeline Holdings, Inc.
Filing Date: 2025-03-26
Form: 424B7
Chunk 12
---
 ability to raise capital under the Purchase Agreement will be limited and/or it will take an extensive time to raise capital, which could prove harmful to us and our ability to meet pir working capital and operation needs through use of the Purchase Agreement.

We generally have the right to control the timing and amount of any sales of our shares to C/M, except that, pursuant to the terms of our agreements with C/M, we would be unable to sell shares to C/M on any day when the closing sale price of our common stock is below $4.00 per share, subject to adjustment as set forth in the Purchase Agreement.

C/M may ultimately purchase all, some or none of the shares of our common stock that may be sold pursuant to the Purchase Agreement in connection with our rights to direct C/M’s purchases at our discretion and, after it has acquired shares, C/M may sell all, some or none of those shares. Therefore, sales to C/M by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to C/M, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

| S-15 |

Further, certain of our outstanding derivatives securities, including convertible preferred stock and warrants, contain anti-dilution price protection provisions which provide for adjustments to conversion and exercise prices, and an increase in the shares underlying such securities, if we sell shares at a per share price below the applicable conversion or exercise price. For example, the Series F, F-1 and G each have a conversion price of $5.10, and the Warrants issued to investors of Series G have an exercise price of $6.50. Therefore, if we issue shares at prices that are lower than these conversion and exercise prices, these conversion prices will automatically be lowered to the new lower sale price. This would cause additional dilution to our common stockholders and result in our receiving less cash upon exercise of warrants. Additionally, because the Company hopes to avoid such an outcome, our ability to raise capital under the ELOC will be limited to the extent our common stock trades near or below these prices.

By virtue of the terms of the Purchase Agreement, it is not possible to predict the number of shares we will sell nor the prices at which we will sell the shares under the Purchase Agreement, nor the consequences (including